MOLOGEN AG Interim Financial Report: Clinical cancer studies are progressing according to plan

Phase II/III of colorectal cancer study with MGN1703 have also begun in Russia

17-Aug-2011 - In the first half of 2011, MOLOGEN AG concentrated above all on its ongoing clinical studies with the cancer medications MGN1703 and MGN1601. Both studies have progressed as planned. Meanwhile the implementation of the phase II/III colorectal cancer study with MGN1703 could also be started in ...

MOLOGEN AG: A Further Clinical Study has Currently been Started - a New Therapy Approach for the Treatment of Renal Cancer

20-Dec-2010 - The Charité - Medical University of Berlin has begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, a cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test ...

Mologen extends clinical study to include another dosing group

28-Jul-2009 - Following positive interim results in the current clinical study with Mologen AG's cancer drug MGN1703, the authorities responsible have approved an extension of the study to include an additional dosing group. This means that the company can now start prompt investigation of the maximum dosage ...

MOLOGEN receives expanded manufacturing authorisation for MIDGE-based active substances

21-Jan-2009 - MOLOGEN AG has received a significantly expanded manufacturing authorisation for its MIDGE®-based DNA active substances. After detailed inspections, the responsible authorities have confirmed that the production and quality of the active substances meets the requirements of the German Medicinal ...

MOLOGEN AG prepares start of clinical study with cancer medicine MGN1703

02-Jun-2008 - MOLOGEN is moving swiftly forward with its preparations for starting the clinical study on the innovative cancer medicine, MGN1703. The aim is to start with patient consumption in a few weeks time. MGN1703 is based on the DNA immunomodulator dSLIM® developed by MOLOGEN. The quantities of the ...

MOLOGEN: Executive Board orients towards new commercial tasks

30-Dec-2004 - MOLOGEN AG in 2004 has set course for successful marketing of its proprietary technologies and projects. In 2005 the new chapter in the development of the company will be supported by changes in the executive board. It will be reduced temporarily from three to two members. Dr. Guido Sandler, ...